REG - LungLife AI, INC - Notice of Results

LungLife AIAnnouncement

08/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220308:nRSH9360Da&default-theme=true

RNS Number : 9360D  LungLife AI, INC  08 March 2022

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Notice of Results

Investor Presentation

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, will announce its full year results for the year ended 31 December
2021 on Monday 28 March 2022.

 

Investor presentation

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial
Officer, will be hosting a live online presentation relating to the full year
results via the Investor Meet Company platform at 4.30pm (GMT) on Tuesday 29
March 2022. The presentation is open to all existing and potential
shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:

https://www.investormeetcompany.com/lunglife-ai-inc/register-investor
(https://www.investormeetcompany.com/lunglife-ai-inc/register-investor)

 

Investors who already follow LungLife on the Investor Meet Company platform
will automatically be invited.

 

Questions can be submitted pre-event via your IMC dashboard or in real time
during the presentation, via the "Ask a Question" function.  Whilst the
Company may not be in a position to answer every question it receives, it will
address the most prominent within the confines of information already
disclosed to the market through regulatory notifications. A recording of the
presentation, a PDF of the slides used, and responses to the Q&A session
will be available on the Investor Meet Company platform afterwards. A
recording of the presentation and a PDF of the slides used will also be
available on the LungLife website: https://investors.lunglifeai.com/media/
(https://investors.lunglifeai.com/media/)

 

 

 

For further information please contact:

 

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Daniel Adams / Virginia Bull / Cameron MacRitchie

 Walbrook PR Limited                                  Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                     (mailto:LungLifeAI@walbrookpr.com)
 Paul McManus / Alice Woodings/ Phillip Marriage     Mob: 07980 541 893 / 07407 804 654/ 07867 984 082

 

About Lunglife AI

 

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORSSDFUWEESEDD